Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catabasis Pharmaceuticals Inc.

www.catabasispharma.com

Latest From Catabasis Pharmaceuticals Inc.

Pipeline Watch: Topline Phase III Results For Caplacizumab, Relugolix, Iclaprim

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Confident Catabasis Takes Positives From Failed Duchenne Trial Into Phase III

The US biotech has presented positive data from a mid-stage trial of edasalonexent that had previously missed its primary endpoint and hopes the goals it has set for Phase III will be enough to satisfy regulators.

Clinical Trials Inflammation

Duchenne Development: Data Sharing May Enable Trials To Move Beyond Six-Minute Walk

Repeated trial failures in this rare disease space have given birth to new alliances – one backed by Critical Path and the other by the CureDuchenne advocacy group – that aim to model disease progression much more accurately through data sharing and rigorous analysis.

Clinical Trials Drug Approval Standards

Catabasis Pursues Bifunctional Mutation-Agnostic Approach To DMD

Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified a NF-κB inhibitor – edasalonexent – as a potential Duchenne muscular dystrophy (DMD) treatment. Speaking at the 2017 Biotech Showcase, Dr Jill Milne, co-founder, president and CEO of Catabasis, describes the company’s ambitions to pursue a pivotal Phase III trial this year.

Rare Diseases Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Catabasis Pharmaceuticals Inc.
  • Senior Management
  • Jill C Milne, PhD, CEO
    Michael Jirousek, PhD, CSO
    Joanne M Donovan, MD, PhD, CMO
    Angelika Fretzen, PhD, SVP, Product Dev.
    Ted Hibben, CBO
    Andrew Nichols, PhD, CSO
  • Contact Info
  • Catabasis Pharmaceuticals Inc.
    Phone: (617) 349-1971
    One Kendall Sq., Bldg. 1400E, Ste. B142
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register